Daily Broadcaster

Multiple Myeloma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Pipeline Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Multiple Myeloma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Pipeline Therapies, Mechanism of Action, Route of Administration, and Developments

September 17
17:32 2021
Multiple Myeloma Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Pipeline Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Multiple Myeloma (MM) – Pipeline Insights, 2021,” report provides comprehensive insights about 80+ companies and 120+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Multiple Myeloma Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Multiple Myeloma pipeline landscapes. 

The report comprises Multiple Myeloma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Multiple Myeloma pipeline products.     

Some of the key takeaways from the Multiple Myeloma Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Cartesian Therapeutics, AbbVie, and Roche, Janssen, Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen Research & Development, Regeneron Pharmaceuticals, Bristol-Myers Squibb/Celgene, BMS/ AstraZeneca, Pfizer (Array Biopharma), BioLineRx, MorphoSys AG/I-Mab Biopharma, Chipscreen Biosciences, etc., are developing therapies for the treatment of Multiple Myeloma.

  • Emerging therapies such as Descartes-11, Venetoclax,  Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M), Keytruda (Pembrolizumab), Cetrelimab (JNJ-63723283), REGN5458, Iberdomide, Imfinzi (Durvalumab; MEDI4736), Braftovi (encorafenib),  Motixafortide (BL-8040), Felzartamab (MOR202), Chidamide (Epidaza), are expected to have a significant impact on the  Multiple Myeloma market in the coming years.

Get an overview of pipeline landscape @ Multiple Myeloma Clinical Trials Analysis  

Multiple myeloma is a cancer of plasma cells. In general, when plasma cells grow to be cancerous and develop out of manipulating, that is known as multiple myeloma. The plasma cells make an ordinary protein acknowledged through several extraordinary names, together with monoclonal immunoglobulin, monoclonal protein (m-protein), m-spike, or paraprotein. Regular plasma cells are determined within the bone marrow and are an enormous part of the immune device.

Multiple Myeloma Pipeline Therapies along with Key Players:

  • Descartes-11 by Cartesian Therapeutics

  • Venetoclax by AbbVie and Roche

  • Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M) by Janssen Biotech/Nanjing Legend Biotech

  • Keytruda (Pembrolizumab) by Merck Sharp & Dohme Corp.

  • Cetrelimab (JNJ-63723283) by Janssen Research & Development

  • REGN5458 by Regeneron Pharmaceuticals

  • Iberdomide by Bristol-Myers Squibb/Celgene

  • Imfinzi (Durvalumab; MEDI4736) by BMS/ AstraZeneca

  • Braftovi (encorafenib) by Pfizer (Array Biopharma)

  • Motixafortide (BL-8040) by BioLineRx

  • Felzartamab (MOR202) by MorphoSys AG/I-Mab Biopharma

  • Chidamide (Epidaza) by Chipscreen Biosciences

  • And others.

Scope of Multiple Myeloma Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Cartesian Therapeutics, AbbVie, and Roche, Janssen, Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen Research & Development, Regeneron Pharmaceuticals, Bristol-Myers Squibb/Celgene, BMS/ AstraZeneca, Pfizer (Array Biopharma), BioLineRx, MorphoSys AG/I-Mab Biopharma, Chipscreen Biosciences, and others.

  • Pipeline Therapies:  Descartes-11, Venetoclax,  Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M), Keytruda (Pembrolizumab), Cetrelimab (JNJ-63723283), REGN5458, Iberdomide, Imfinzi (Durvalumab; MEDI4736), Braftovi (encorafenib),  Motixafortide (BL-8040), Felzartamab (MOR202), Chidamide (Epidaza), and others.

Table of Contents

1

Multiple Myeloma Report Introduction

2

Multiple Myeloma Executive Summary

3

Multiple Myeloma Overview

4

Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment

5

Multiple Myeloma Pipeline Therapeutics

6

Multiple Myeloma Late Stage Products (Phase II/III)

7

Multiple Myeloma Mid Stage Products (Phase II)

8

Multiple Myeloma Early Stage Products (Phase I)

9

Multiple Myeloma Preclinical Stage Products

10

Multiple Myeloma Therapeutics Assessment

11

Multiple Myeloma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Multiple Myeloma Key Companies

14

Multiple Myeloma Key Products

15

Multiple Myeloma Unmet Needs

16 

Multiple Myeloma Market Drivers and Barriers

17

Multiple Myeloma Future Perspectives and Conclusion

18

Multiple Myeloma Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Multiple Myeloma Market

DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.

Multiple Myeloma Epidemiology

DelveInsight’s Multiple Myeloma – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/